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journal homepage: http: / /www.pediatr -neonatol .comEDITORIALPulmonary Drug Delivery by SurfactantExogenous surfactant and early use of nasal continuous
positive airway pressure significantly decreased the inci-
dence and severity of respiratory distress syndrome (RDS)
and improved the survival of preterm infants. However, the
incidence of RDS-related complication-chronic lung disease
(CLD) is still high.1,2 This may be due to the multifactorial
etiology of CLD. Recently, Huang et al3 reported that
combined administration of surfactant and budesonide
further increased the fluorescent intensity in the lungs of
mice compared with the control condition. This study may
give us an alternative therapeutic strategy for not only
treating RDS but also for preventing the subsequent
development of CLD in preterm infants.
The causes of bronchopulmonary dysplasia (BPD) include
immaturity, genetic susceptibility, prolonged oxygen ther-
apy, barotrauma, inflammation, and nutritional defi-
ciency.4 Among these factors, inflammation induced by
oxygen therapy or sepsis plays an important role in the
pathogenesis of CLD in preterm infants, especially for those
with RDS. Therefore, systemic glucocorticoids have been
used to prevent or treat CLD in preterm infants who
required prolonged mechanical ventilation by suppressing
the lung inflammation. However, because of the systemic
adverse effects on neurodevelopmental outcome, systemic
glucocorticoids are not recommended for routine use now.5
So far, no effective therapy has been proven useful in
preventing CLD in preterm infants.
Because preterm infants complicated with RDS require
oxygen therapy or ventilator support right after birth, the
CLD-related inflammatory process may also start as early as
the first breath. Thus, intratracheal delivery steroid with
surfactant for preterm infants with RDS may have the ad-
vantages of early prevention of inflammation and of
decreasing the side effects of the steroid due to local
treatment rather than systemic therapy. Previously Yeh
et al6 demonstrated that early postnatal intratracheal
instillation of budesonide using surfactant as a vehicle
significantly improved the combined outcome of death or
chronic lung disease, and also increased the number of
survivors without CLD. However, the pulmonary distributionhttp://dx.doi.org/10.1016/j.pedneo.2014.11.001
1875-9572/Copyright ª 2014, Taiwan Pediatric Association. Published bof budesonide is not clear. By using the in vivo image sys-
tem, Huang et al3 demonstrated that mice treated with
both surfactant and budesonide showed a significant in-
crease in fluorescent intensity compared with mice treated
with either surfactant or budesonide alone. These data
show that surfactant is not only powerful for treating RDS,
but also that surfactant alone or with budesonide can be
used as an effective vehicle for pulmonary drug delivery.Conflicts of interest
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